PMID- 26349667
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20171206
IS  - 1724-6008 (Electronic)
IS  - 0393-6155 (Linking)
VI  - 31
IP  - 1
DP  - 2016 Feb 28
TI  - Evaluation of HER2 by automated FISH and IHC in gastric carcinoma biopsies.
PG  - e38-43
LID - 18F87BC0-A6C6-4171-BF28-BC9106468B77 [pii]
LID - 10.5301/jbm.5000169 [doi]
AB  - PURPOSE: The use of trastuzumab (Herceptin) to target HER2 has been applied in 
      breast carcinoma and gastric carcinoma (GC). Previous studies have tested 
      trastuzumab's effectiveness by assessing HER2 expression or HER2 amplification by 
      means of immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). 
      In this work we aimed to evaluate automated FISH and IHC technologies for HER2 
      detection in GC biopsies to be used in routine pathology practice. METHODS: The 
      study used an Oracle HER2 IHC System and an LSI HER2/CEP17 Dual Probe on an 
      automated Bond system (Leica Microsystems). One hundred GC biopsies were 
      evaluated including 44 intestinal type, 38 diffuse type and 18 indeterminate type 
      according to Lauren's classification. RESULTS: The overall concordance rate 
      between the automated FISH and IHC methods was 94% (kappa = 0.87), as 6 samples were 
      scored as equivocal (4 in IHC and 2 in FISH). Moreover, HER2 positivity was 
      significantly different between the 3 types of GC (p<0.05), being more frequent 
      in intestinal-type GC (23%) than in the other 2 histological types (5% and 0%). 
      Finally, the HER2/CEP17 FISH ratio was significantly different (p<0.01) between 
      disomic and polysomic samples, being higher in polysomic samples (mean 1.633 +/- 
      0.509) than in disomic samples (mean 1.231 +/- 0.675). CONCLUSIONS: Automated HER2 
      testing of GC biopsies using the Leica Bond system was useful and efficient. This 
      method allowed us to improve normal routine procedures, minimizing time and costs 
      as well as handling and observation errors.
FAU - Silva, Maria R
AU  - Silva MR
AD  - Anatomical Pathology Institute, Faculty of Medicine of the University of Coimbra, 
      Coimbra - Portugal.
FAU - Alarcao, Ana
AU  - Alarcao A
AD  - Anatomical Pathology Institute, Faculty of Medicine of the University of Coimbra, 
      Coimbra - Portugal.
FAU - Ferreira, Teresa
AU  - Ferreira T
AD  - Anatomical Pathology Institute, Faculty of Medicine of the University of Coimbra, 
      Coimbra - Portugal.
FAU - d'Aguiar, Maria
AU  - d'Aguiar M
AD  - Anatomical Pathology Institute, Faculty of Medicine of the University of Coimbra, 
      Coimbra - Portugal.
FAU - Ladeirinha, Ana
AU  - Ladeirinha A
AD  - Anatomical Pathology Institute, Faculty of Medicine of the University of Coimbra, 
      Coimbra - Portugal.
FAU - Balseiro, Sandra
AU  - Balseiro S
AD  - Anatomical Pathology Institute, Faculty of Medicine of the University of Coimbra, 
      Coimbra - Portugal.
AD  - Polytechnic Institute of Castelo Branco, Superior Health School Dr. Lopes Dias, 
      Castelo Branco - Portugal.
FAU - Carvalho, Lina
AU  - Carvalho L
AD  - Anatomical Pathology Institute, Faculty of Medicine of the University of Coimbra, 
      Coimbra - Portugal.
LA  - eng
PT  - Journal Article
DEP - 20160228
PL  - United States
TA  - Int J Biol Markers
JT  - The International journal of biological markers
JID - 8712411
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Biomarkers, Tumor/*biosynthesis/genetics
MH  - Biopsy
MH  - Carcinoma/*diagnosis/genetics/pathology
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/*biosynthesis/genetics
MH  - Stomach Neoplasms/*diagnosis/genetics/pathology
MH  - Trastuzumab/therapeutic use
EDAT- 2015/09/10 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/09/10 06:00
PHST- 2015/07/22 00:00 [accepted]
PHST- 2015/09/10 06:00 [entrez]
PHST- 2015/09/10 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 18F87BC0-A6C6-4171-BF28-BC9106468B77 [pii]
AID - 10.5301/jbm.5000169 [doi]
PST - epublish
SO  - Int J Biol Markers. 2016 Feb 28;31(1):e38-43. doi: 10.5301/jbm.5000169.